Moderna chief executive Stephane Bancel said on Tuesday he hopes U.S. and international regulators approve many coronavirus vaccines to enter the market, adding that “no manufacturers can make enough doses for the planet.”
Moderna is moving into a phase 2 trial for its vaccine and is finalising plans for the third phase trial as early as this summer.
Regeneron’s chief executive Leonard Schleifer, whose company is developing an antibody drug with plans to enter human trials in June, told CNBC that the problem isn’t with the physical distribution of a potential coronavirus drug, which could be made available by major retail chains, but rather with the ability to meet the enormous demand.
Schleifer said multiple companies will need to succeed in the development of their coronavirus therapeutics as “the demand will far exceed the capacity.”
